Clear All
793 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
Q5166 Denosumab-desu Jubereq, Osvyrti 1mg Immunotherapy Monoclonal Antibody RANKL No 2026 Jun 17, 2026 In Use
S0156 Exemestane Aromasin 25 mg Hormonal Therapy Aromatase Inhibitor Yes 1999 Jan 1, 2001 In Use
Q5101 Filgrastim Neupogen, Zarxio 1 mcg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 1991 Jul 1, 2015 In Use
N/A Calcium folinate Lederle Leucovorin 5mg Ancillary Therapy Chemoprotective Antidote Yes 2025 In Use
J9225 Histrelin Acetate Vantas 50 mg Hormonal Therapy GnRH Agonist No 2004 Jan 1, 2008 In Use
NA Fluoxymesterone Androxy 10 mg Hormonal Therapy Androgen Yes 1983 In Use
J1434 Fosaprepitant Focinvez 1mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 No 2023 Apr 17, 2024 In Use
J1456 Fosaprepitant (Teva) Fosaprepitant (Teva) 1mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 No 2019 Dec 21, 2022 In Use
NA Gardasil-9 Human papillomavirus vaccine Ancillary Therapy Protective Agent HPV Vaccine No 2016 In Use
NA Anastrozole Arimidex 0.5 mg Hormonal Therapy Aromatase Inhibitor Yes 1995 In Use
J1453 Fosaprepitant Emend 150 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 No 2008 Jan 1, 2009 In Use
N/A Dordaviprone MODEYSO 125mg Chemotherapy Protease Activator ClpP, dopamine D2 Yes 2025 In Use
J9300 Gemtuzumab ozogamicin Mylotarg 5 mg Immunotherapy Drug Antibody Conjugate CD33 No 2000 Jan 1, 2002 In Use
J1627 Granisetron Hydrochloride Extended Release Granisol [DSC], Sancuso, Sustol, Kytril 0.1 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 2016 Jan 1, 2018 In Use
J8530 Cyclophosphamide Cyclophosphamide oral 25 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1959 Jan 1, 1995 In Use
J9173 Durvalumab Imfinzi 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Jan 1, 2019 In Use
S2107 Immunotherapy - non specific Adoptive immunotherapy (ie development of specific anti-tumor reactivity) NA Immunotherapy No Apr 1, 2002 In Use
J3590 Immunotherapy - non specific Unclassified biologics NA Immunotherapy No Jan 1, 2003 In Use
J9216 Interferon Gamma-1b Actimmune 3 million units Immunotherapy Cytokine Interferon No 1999 Jan 1, 2009 In Use
Q0167 Dronabinol Marinol 2.5 mg Ancillary Therapy Antiemetic CB1/CB2 Yes 1985 Apr 1, 1998 In Use
NA Encorafenib Braftovi 50mg, 75mg Chemotherapy BRAF Inhibitor V600E Yes 2018 In Use
J9206 Irinotecan Camptosar 20 mg Chemotherapy Topoisomerase I Inhibitor Campothecin Analogs No 1996 Jan 1, 1998 In Use
J9227 Isatuximab-irtc Sarclisa 10mg Immunotherapy Monoclonal Antibody CD38 No 2020 Oct 1, 2020 In Use
NA Lapatinib Tykerb 250 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2007 In Use
Q5162 Denosumab-nxxp Bildyos/Bilprevda 1mg Immunotherapy Monoclonal Antibody RANKL No 2026 Mar 18, 2026 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.